Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML

Trial Details

NCT ID
NCT05305859
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • venetoclax combining chidamide and azacitidine (VCA)
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology
  • Life expectancy ≥ 3 months
  • Adequate laboratory parameters during the screening period as evidenced by the following:
  • Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →